French National Authority for Health assessment of metabolic surgery for type 2 diabetes remission—A meta-analysis in patients with class I to III obesity
Pooled result · DR, patients with obesityResult — go to the resultRelative risk 6.65 95 % CI 2.24–19.79Authors' conclusion
Although the data available in patients with class I obesity and type 2 diabetes remains limited, MA shows higher rates of DR after MS compared with MT after 36 months' follow-up in these patients. Consequently, the French National Authority for Health French (HAS) recommends MS for these patients.
Study context
- Population
- Patients with obesity (class I to III) and T2D; Randomized controlled trials (RCTs) in Medline, Cochrane Library, Embase and LiSSA, January 2008–September 20225 trials (36 months)
- Participants
- 404 patients
- Comparison
- Metabolic surgery vs medical therapy
- Outcome
- Diabetes remission (DR)
Methodological detailsMantel-Haenszel random-effects, ≥24-month follow-up
- Mantel-Haenszel random-effects
- ≥24-month follow-up
Pooled result
DR, patients with obesity · 36 months
Relative risk
6.65
95 % CI 2.24–19.79
MSvs MT
RR 6.65 (95 % CI 2.24–19.79)
As reported in the abstract
Further pooled results
| Outcome | RR (CI) | |
|---|---|---|
| DR, class I obesity · 36 monthsI² = 0 %; 4 trials, 80 patients | 5.27 (1.31–21.23) | |
| 0.050.21520Relative risk (log scale) |
Additional meta-analysis (MAs) in patients with obesity · 24, 36 and 60 months
- All additional MAs favor metabolic surgery (MS) (specifically Roux-en-Y gastric bypass) over medical therapy (MT) at 24, 36 (only) and 60 months
Original publication
French National Authority for Health assessment of metabolic surgery for type 2 diabetes remission—A meta-analysis in patients with class I to III obesity. Diabetes Metab. Published 22 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →